Who Are The Most Impactful Cannabis Executives Of 2022? Top Award Show Will Determine Who’s #1
After the awesome Cannabis Capital Conference in Miami during 4/20 week, Benzinga is ready to go again in Chicago on September 13-14.
Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report
Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc.
Psychedelic Biotech Gets U.K. Study Approval In Treatment Of Depression
Short-acting psychedelics company Small Pharma Inc. (OTCQB: DMTTF) has received the approval from the U.K.
MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes
MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offer
With EFT Defiance Psychedelics Fund Closing, Let’s Take A Look At Market Movement
The fund owning the Defiance Next Gen Altered Experience ETF (NYSEARCA: PSY) and Defiance Next Gen SPAC Derived ETF funds, ETF Series Solutions recently decided to close and liquidate each fund.
What’s Going On With MindMed? Co-Founder Dr. Scott Freeman Lays Out ‘Value Enhancement Plan’
FCM MM Holdings sent a letter to MindMed’s (NASDAQ: MNMD) board of directors calling on them to adopt a new strategic plan to "turn the company around.”
Lobe Sciences Signs Exclusive Deal For Psilocin Clinical Trials In Australia
Life sciences company Lobe Sciences Ltd.
Meet Blue Serenity, Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
The Canadian-based company licensed by Health Canada for psychedelic and functional mushrooms production, Optimi Health Corp.
This Psychedelics Company Is Setting Up An Equity Program For Up To $35M In Shares
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) has launched an at-the-market (ATM) equity program through which it will issue and sell up to $35 million in common shares in the company’s capital, from the treasury to the public.